Jesse I Treu - Net Worth and Insider Trading

Jesse I Treu Net Worth

The estimated net worth of Jesse I Treu is at least $113 Million dollars as of 2024-04-26. Jesse I Treu is the 10% Owner of Achillion Pharmaceuticals Inc and owns about 8,032,129 shares of Achillion Pharmaceuticals Inc (ACHN) stock worth over $54 Million. Jesse I Treu is the Director of Veracyte Inc and owns about 1,234,930 shares of Veracyte Inc (VCYT) stock worth over $24 Million. Jesse I Treu is also the 10% Owner of Zogenix Inc and owns about 825,323 shares of Zogenix Inc (ZGNX) stock worth over $22 Million. Besides these, Jesse I Treu also holds Aldeyra Therapeutics Inc (ALDX) , Esperion Therapeutics Inc (ESPR) , Alimera Sciences Inc (ALIM) , Ocera Therapeutics Inc (OCRX) , Clovis Oncology Inc (CLVSQ) , Orexigen Therapeutics Inc (OREXQ) , Novation Companies Inc (NOVCQ) , Regado Biosciences Inc (RGDO) . Details can be seen in Jesse I Treu's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jesse I Treu has not made any transactions after 2019-03-26 and currently still holds the listed stock(s).

Transaction Summary of Jesse I Treu

To

Jesse I Treu Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jesse I Treu owns 31 companies in total, including Aldeyra Therapeutics Inc (ALDX) , Obalon Therapeutics Inc (OBLN) , and Adynxx Inc (ADYX) among others .

Click here to see the complete history of Jesse I Treu’s form 4 insider trades.

Insider Ownership Summary of Jesse I Treu

Ticker Comapny Transaction Date Type of Owner
ALDX Aldeyra Therapeutics Inc 2019-03-26 director & 10 percent owner
OBLN Obalon Therapeutics Inc 2019-08-06 10 percent owner
ADYX Adynxx Inc 2019-05-03 10 percent owner
VCYT Veracyte Inc 2019-03-04 director & 10 percent owner
BNGO Bionano Genomics Inc 2018-08-21 10 percent owner
DRNA Dicerna Pharmaceuticals Inc 2017-12-18 10 percent owner
OCRX Ocera Therapeutics Inc 2017-12-11 10 percent owner
TNDM Tandem Diabetes Care Inc 2013-11-13 director & 10 percent owner
RGDO Regado Biosciences Inc 2016-11-01 10 percent owner
CLCD CoLucid Pharmaceuticals Inc 2016-09-09 10 percent owner
EVOK Evoke Pharma Inc 2013-09-24 10 percent owner
SNDX Syndax Pharmaceuticals Inc 2016-03-02 10 percent owner
GKOS Glaukos Corp 2015-06-24 10 percent owner
LIFE aTyr Pharma Inc 2015-05-06 10 percent owner
ESPR Esperion Therapeutics Inc 2013-07-01 10 percent owner
EVFM Evofem Biosciences Inc 2014-11-19 10 percent owner
ATRA Atara Biotherapeutics Inc 2014-10-15 10 percent owner
OTIC Otonomy Inc 2014-08-12 10 percent owner
MRNS Marinus Pharmaceuticals Inc 2014-07-31 10 percent owner
AKAOQ Achaogen Inc 2014-03-17 10 percent owner
ALIM Alimera Sciences Inc 2011-06-02 10 percent owner
CLVSQ Clovis Oncology Inc 2011-11-21 10 percent owner
ACHN Achillion Pharmaceuticals Inc 2013-01-18 10 percent owner
CPXX Celator Pharmaceuticals Inc 2013-01-14 10 percent owner
OREXQ Orexigen Therapeutics Inc 2011-12-22 10 percent owner
ZGNX Zogenix Inc 2011-09-16 10 percent owner
PRTK Paratek Pharmaceuticals Inc 2006-05-09 10 percent owner
VNDA Vanda Pharmaceuticals Inc 2006-04-12 10 percent owner
SNMX Senomyx Inc 2004-06-25 10 percent owner
NUVA NuVasive Inc 2004-05-12 10 percent owner
RSLS Reshape Lifesciences Inc 2016-10-05 10 percent owner

Jesse I Treu Latest Holdings Summary

Jesse I Treu currently owns a total of 11 stocks. Among these stocks, Jesse I Treu owns 8,032,129 shares of Achillion Pharmaceuticals Inc (ACHN) as of August 20, 2010, with a value of $54 Million and a weighting of 47.88%. Jesse I Treu owns 1,234,930 shares of Veracyte Inc (VCYT) as of March 4, 2019, with a value of $24 Million and a weighting of 21.21%. Jesse I Treu also owns 825,323 shares of Zogenix Inc (ZGNX) as of November 29, 2010, with a value of $22 Million and a weighting of 19.42%. The other 8 stocks Aldeyra Therapeutics Inc (ALDX) , Esperion Therapeutics Inc (ESPR) , Alimera Sciences Inc (ALIM) , Ocera Therapeutics Inc (OCRX) , Clovis Oncology Inc (CLVSQ) , Orexigen Therapeutics Inc (OREXQ) , Novation Companies Inc (NOVCQ) , Regado Biosciences Inc (RGDO) have a combined weighting of 11.49% among all his current holdings.

Latest Holdings of Jesse I Treu

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ACHN Achillion Pharmaceuticals Inc 2010-08-20 8,032,129 6.76 54,297,192
VCYT Veracyte Inc 2019-03-04 1,234,930 19.48 24,056,436
ZGNX Zogenix Inc 2010-11-29 825,323 26.68 22,019,618
ALDX Aldeyra Therapeutics Inc 2019-03-26 1,885,854 3.94 7,430,265
ESPR Esperion Therapeutics Inc 2013-07-01 2,102,188 1.99 4,183,354
ALIM Alimera Sciences Inc 2011-06-02 279,297 3.31 924,473
OCRX Ocera Therapeutics Inc 2013-07-15 246,386 1.79 441,031
CLVSQ Clovis Oncology Inc 2011-11-21 3,041,950 0.02 45,629
OREXQ Orexigen Therapeutics Inc 2011-12-22 301,806 0.01 1,600
NOVCQ Novation Companies Inc 2006-05-15 1,062,474 0.00 106
RGDO Regado Biosciences Inc 2013-08-27 2,603,208 0.00 0

Holding Weightings of Jesse I Treu


Jesse I Treu Form 4 Trading Tracker

According to the SEC Form 4 filings, Jesse I Treu has made a total of 0 transactions in Achillion Pharmaceuticals Inc (ACHN) over the past 5 years. The most-recent trade in Achillion Pharmaceuticals Inc is the sale of 0 shares on August 20, 2010, which brought Jesse I Treu around $0.

According to the SEC Form 4 filings, Jesse I Treu has made a total of 0 transactions in Veracyte Inc (VCYT) over the past 5 years. The most-recent trade in Veracyte Inc is the sale of 1,052,151 shares on March 4, 2019, which brought Jesse I Treu around $21 Million.

According to the SEC Form 4 filings, Jesse I Treu has made a total of 0 transactions in Zogenix Inc (ZGNX) over the past 5 years. The most-recent trade in Zogenix Inc is the acquisition of 293,750 shares on November 29, 2010, which cost Jesse I Treu around $9 Million.

More details on Jesse I Treu's insider transactions can be found in the Insider Trading History of Jesse I Treu table.

Insider Trading History of Jesse I Treu

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jesse I Treu Trading Performance

GuruFocus tracks the stock performance after each of Jesse I Treu's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jesse I Treu is 13.44%. GuruFocus also compares Jesse I Treu's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jesse I Treu within 3 months outperforms 5 times out of 21 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jesse I Treu's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jesse I Treu

Average Return

-10.03%

Average return per transaction

Outperforming Transactions

29%

6 out of 21 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 13.79 13.44 18.78 -10.03 -21.41 -11.18
Relative Return to S&P 500(%) 10.5 8.42 10.72 -22.53 -32.48 -21.59

Jesse I Treu Ownership Network

Ownership Network List of Jesse I Treu

No Data

Ownership Network Relation of Jesse I Treu


Jesse I Treu Owned Company Details

What does Aldeyra Therapeutics Inc do?

Who are the key executives at Aldeyra Therapeutics Inc?

Jesse I Treu is the director & 10 percent owner of Aldeyra Therapeutics Inc. Other key executives at Aldeyra Therapeutics Inc include 10 percent owner Perceptive Life Sciences Master Fund Ltd , Chief Development Officer Stephen Machatha , and director & President and CEO Todd C Brady .

Aldeyra Therapeutics Inc (ALDX) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Aldeyra Therapeutics Inc (ALDX). Other recent insider transactions involving Aldeyra Therapeutics Inc (ALDX) include a net sale of 2,074,234 shares made by Perceptive Life Sciences Master Fund Ltd , a net sale of 41,305 shares made by Stephen Machatha , and a net sale of 26,402 shares made by Bruce Greenberg .

In summary, during the past 3 months, insiders sold 250,945 shares of Aldeyra Therapeutics Inc (ALDX) in total and bought 682,265 shares, with a net purchase of 431,320 shares. During the past 18 months, 3,007,444 shares of Aldeyra Therapeutics Inc (ALDX) were sold and 682,265 shares were bought by its insiders, resulting in a net sale of 2,325,179 shares.

Aldeyra Therapeutics Inc (ALDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aldeyra Therapeutics Inc Insider Transactions

No Available Data

Jesse I Treu Mailing Address

Above is the net worth, insider trading, and ownership report for Jesse I Treu. Currently GuruFocus does not have mailing address information for Jesse I Treu.

Discussions on Jesse I Treu

No discussions yet.